Denosumab Drug Asset Due Diligence Report 2026

This Denosumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

395

Registered trials

372

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Denosumab can convert its Monoclonal antibody profile and RANKL biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Denosumab (query alias: denosumab)
Modality / target	Monoclonal antibody; RANKL; RANKL inhibitors
Highest global status	Approved
Originator	Amgen, Inc.
Active developers	Amgen, Inc., Amgen Australia Pty Ltd., Amgen Europe BV

The MCP disease footprint includes Bone Diseases, Glucocorticoid-induced osteoporosis, Humoral Hypercalcemia of Malignancy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT1041250187	Not Applicable	募集中	144	Percent change in lumbar spine bone mineral density (BMD)
NCT07546552	Not Applicable	Recruiting	100	Evaluate and compare the reproductive phenotype of granulosa cell-specific Rankl knock down mice, global Rankl knock out mice, and a humanized RANKL mouse model treated with denosumab.
NCT07410442	Not Applicable	Recruiting	50	Incidence and severity of soft tissue complications adjacent to the distal shoe appliance

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

EFFECT OF DENOSUMAB ON IMPLANT SURVIVAL FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY IN OSTEOARTHRITIS PATIENTS: A REGISTRY-BASED DATA LINKAGE STUDY

Not Applicable; n=2050; evaluation: Negative. Reported fields: Implant survival = high in both groups, with no significant difference between treatments (Figure 1; log-rank p=0.608). ; Implant survival = high in both groups, with no significant difference between treatments (Figure 1; log-rank p=0.608). ; Implant survival = high in both groups, with no significant difference between treatments (Figure 1; log-rank p=0.608).

TREAT-TO-TARGET APPROACH IN OSTEOPOROSIS: A REAL-WORLD COMPARISON OF TERIPARATIDE AND DENOSUMAB

Not Applicable; n=44; evaluation: Similar. Reported fields: Target attainment(Among patients below target at baseline) = 36.4 % ; Target attainment(Among patients below target at baseline) = 17.6 %

Staged dose escalation of adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer: First safety and efficacy data from a Russian cohort.

Not Applicable; n=64; evaluation: Positive. Reported fields: AE(grade 3) = 7.8 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Denosumab addresses Bone Diseases, Glucocorticoid-induced osteoporosis, Humoral Hypercalcemia of Malignancy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-10-31	Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China	Approved	Financial terms not disclosed
2017-09-13	Chong Kun Dang, Amgen Korea to Jointly Sell Osteoporosis Drug Prolia	Approved	Financial terms not disclosed
2016-09-16	Dr. Reddy’s Expands Strategic Collaboration with Amgen in India	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Stable pharmaceutical composition of Anti-rankl antibody”. The milestone feed surfaced a patent-application signal described as “Binding agent of anti-RANKL monoclonal antibody or derivative thereof and application of binding agent”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO